Key Takeaways
- New executive order: Executive Order 14437, “Advancing Women’s Health to Improve Outcomes in All Phases of Life,” was signed on October 19, 2026.
- Two new bodies: It directs the creation of a Women’s Health Division at the National Institutes of Health within 90 days and establishes a White House Women’s Health Task Force.
- Menopause is named: The order lists menopause among the conditions needing more research and calls for stage-specific care from adolescence through midlife and aging.
- No immediate change to care: The order does not create new coverage or legal rights, and its actions depend on available funding.
What Happened
On October 19, 2026, the President signed an executive order on women’s health. It directs the Secretary of Health and Human Services, working through the NIH director, to set up a Women’s Health Division within an appropriate NIH institute or center within 90 days, which puts the deadline around mid-January 2027. The division is to work with the existing NIH Office of Research on Women’s Health.
The order also creates the White House Women’s Health Task Force, co-chaired by the Secretary of Health and Human Services and the White House Chief of Staff. Its members include the heads of agencies such as the FDA, CDC, NIH, CMS, the Department of Veterans Affairs, the Department of Labor and the Department of War. The order revokes two earlier actions: Executive Order 14120 from March 2024 and a November 2023 presidential memorandum on women’s health research.
Why It Matters
The order states that many conditions affecting women have received less research and clinical attention than others. Its list of research gaps includes heart disease, cancer, stroke, Alzheimer’s disease, osteoporosis, mental health, chronic pain, endometriosis, infertility, maternal health and menopause. It sets a policy of connecting research to clinical care and recognizing health needs through pregnancy, midlife, menopause and aging.
This is part of a busy few weeks for midlife health policy. HHS announced new hormone therapy labeling and supply updates on October 30 (see our story on the FDA estradiol patch announcement) and said that work supports this order.
What This Means for Women in Perimenopause and Menopause
Nothing about your treatment options changes today. The potential impact is longer term. Among the task force’s listed priorities are accelerating research that translates into clinical practice, updating clinical education based on current science, strengthening primary care, specialty care and behavioral health integration, and ensuring a robust supply of providers and medical products. For women in midlife, that could eventually mean more research funding, better clinician training and more attention to symptoms that have been under-studied.
In the meantime, you can learn what’s available now in our HRT 101 guide and track your own symptoms with our symptom trackers.
Access and Availability
The order does not approve any treatment, change insurance coverage or create a new benefit. It states that it does not create rights or benefits enforceable by any party, and that it will be carried out consistent with applicable law and subject to available appropriations. To find a clinician with menopause expertise now, use our menopause specialist directory.
Benefits and Risks
Supporters of research-focused initiatives point to the potential for better science and clearer clinical guidance in areas that have lagged. Open questions include how the new NIH division will be funded and staffed, how it will relate to existing offices, and how the task force’s goals will be measured. The order sets a direction rather than specific funding amounts or timelines beyond the 90-day NIH deadline.
Next Steps: What to Watch For
Watch for the NIH’s announcement of where the Women’s Health Division will sit, the first task force meetings or public hearings (the co-chairs may hold them and take expert input), and any funding announcements tied to menopause and midlife research. We’ll also be watching how this fits with professional guidance, like the new ACOG menopause guideline.
What This Means for Your Midlife Health
More attention on menopause at the federal level is a notable shift, but your care still happens in the exam room. Come prepared with your symptoms, your questions and your priorities. Our symptoms by category page is a good place to start. We’ll keep following this story so you’ll know when changes reach you.
Frequently Asked Questions
What does the women’s health executive order do?
It directs the NIH to create a Women’s Health Division within 90 days, establishes a White House Women’s Health Task Force and sets a policy of translating women’s health research into clinical care across life stages, including menopause.
Does the executive order change menopause treatment or insurance coverage?
No. It does not approve treatments or alter coverage. It sets up bodies and priorities that may shape future research and policy.
Does the order mention menopause specifically?
Yes. Menopause appears in the list of areas needing more research and in the policy of providing stage-specific care through midlife, menopause and aging.
What happened to earlier women’s health orders?
The new order revokes Executive Order 14120 of March 2024 and a presidential memorandum from November 2023 on women’s health research.
This article is for informational purposes only and is not medical advice. Please consult a qualified healthcare provider about your symptoms and treatment options.
References
- The White House. (2026). Advancing Women’s Health to Improve Outcomes in All Phases of Life (Executive Order 14437).
- HHS. (2026). Trump Administration Delivers for Women with Major Advances in Menopause Care.